1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16. 2. Treatment-related adverse events were infrequent with one fatality across both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Hidradenitis suppurativa (HiS) is a chronic inflammatory disease with limited therapeutic options. Bimekizumab, a monoclonal IgG1 antibody that